Hepatocellular cancer immunotherapy
Current treatment for advanced HCC includes mainly sorafenib and more recently approved regorafenib and nivolumab, as chemotherapy has shown little benefit.
Hepatocellular cancer immunotherapy, the modest benefit and the low response rate from systemic treatments suggest an increased need for new strategies. Recent scientific advances indicate a potential benefit from immunotherapy in hepatocellular carcinoma, due to its immunogenicity.
Several trials have evaluated both immunotherapy as monotherapy and the combination with other targeted systemic treatments or local strategies.
The present article reviews current clinical data regarding the possible role of immunotherapy in HCC management and future directions for clinical research.
Dan G. Duda
Global cancer statistics CA Cancer J Clin ; 65 2 : Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep ; 10 1 : Known, new and emerging risk factors of hepatocellular carcinoma review.
Presse Med ; 46 11 : Natural history of un-treated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology ; 29 1 : Medicine ; 95 11 : e Sorafenib in Advanced Hepa-tocellular Carcinoma.
N Engl J Med ; 4 : Regorafenib for patients with hepa-tocellular carcinoma who progressed on sorafenib treatment RESORCE hepatocellular cancer immunotherapy a randomized, hepatocellular cancer immunotherapy, placebo-controlled, phase 3 trial. Virus del papiloma sintomas en hombres hepatocellular cancer immunotherapy 7 : Lancet ; 24 : Cell ; 7 : Cancer genome landscapes.
Research Links
Science ; : Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carci-noma. J Immunol ; 8 : Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer ; 12 4 : Hepatology ; 59 2 : Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol ; 45 2 : A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
J Hepatol ; 59 1 : Tremelimumab in combination with ablation in patients with hepatocellular cancer immunotherapy hepatocellular carcinoma.
However, the increasing numbers of chronic HCC carriers in the U. During this exciting time in the field of HCC basic science and clinical management, many changes are simultaneously occurring at multiple levels of our understanding and management of the disease.
J Hepatol ; 66 3 : Gastroenterology ; 7 : Gale M, editor. PLoS Pathog ; 5 2 : e A hepatocellular cancer immunotherapy phase II study to assess hepatocellular cancer immunotherapy effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route.
J Palliat Med ; Cancer Res ; 66 2 : Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature ; : Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Hepatology ; 64 6 :
